Kura Oncology (NASDAQ:KURA – Get Free Report) and Cue Biopharma (NASDAQ:CUE – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.
Insider and Institutional Ownership
35.0% of Cue Biopharma shares are held by institutional investors. 7.6% of Kura Oncology shares are held by company insiders. Comparatively, 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Kura Oncology and Cue Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kura Oncology | -384.30% | -207.18% | -45.17% |
| Cue Biopharma | -435.83% | -482.58% | -282.39% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kura Oncology | 1 | 2 | 10 | 0 | 2.69 |
| Cue Biopharma | 1 | 0 | 0 | 0 | 1.00 |
Kura Oncology presently has a consensus price target of $25.62, indicating a potential upside of 102.91%. Given Kura Oncology’s stronger consensus rating and higher possible upside, equities analysts plainly believe Kura Oncology is more favorable than Cue Biopharma.
Valuation and Earnings
This table compares Kura Oncology and Cue Biopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kura Oncology | $67.48 million | 16.61 | -$278.67 million | ($3.37) | -3.75 |
| Cue Biopharma | $27.47 million | 3.97 | -$26.60 million | ($27.02) | -0.96 |
Cue Biopharma has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Kura Oncology has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500.
Summary
Kura Oncology beats Cue Biopharma on 9 of the 14 factors compared between the two stocks.
About Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
